PURPOSE: The molecular chaperone heat shock protein 90 (HSP90) plays an important role in several types of tumors also participating in the modulation of the activity of receptor tyrosine kinases activity such as members of the Her family. We evaluated the significance of HSP90 and Her2 expression in colon cancer. METHODS: HSP90 and Her2 expression was determined by immunohistochemistry and by fluorescence in situ hybridization (FISH) on 355 primary resected colon carcinomas. Results were correlated with pathologic features (Union for International Cancer Control (UICC) pTNM category, tumor localisation, tumor differentiation), additional molecular genetic characteristics (BRAF, KRAS mutational status, mismatch repair genes (MMR)), and survival. RESULTS: HSP90 immunoreactivity was observed in various degrees. Fifty-one cases (14 %) were positive for Her2 (score 2+ and 3+) with 16/43 cases with Her2 2+ staining pattern showing amplification of Her2 determined by FISH. There was a significant correlation between high HSP90 expression and Her2 overexpression (p = 0.011). High HSP90 expression was associated with earlier tumor stages (p = 0.019), absence of lymph node (p = 0.006), and absence of distant metastases (p = 0.001). Patients with high tumoral HSP90 levels had a better survival (p = 0.032), but this was not independent from other prognostic relevant pathologic parameters. Her2 expression was not associated with any of the investigated histopathological, molecular, or clinical parameters. CONCLUSIONS: High HSP90 levels are reflecting lower malignant potential in colon cancer. Her2 positivity can be observed in a small number of cases. Targeting HSP90 and/or Her2 may be an alternative therapeutic approach in colon cancer in a subset of patients.
PURPOSE: The molecular chaperone heat shock protein 90 (HSP90) plays an important role in several types of tumors also participating in the modulation of the activity of receptor tyrosine kinases activity such as members of the Her family. We evaluated the significance of HSP90 and Her2 expression in colon cancer. METHODS:HSP90 and Her2 expression was determined by immunohistochemistry and by fluorescence in situ hybridization (FISH) on 355 primary resected colon carcinomas. Results were correlated with pathologic features (Union for International Cancer Control (UICC) pTNM category, tumor localisation, tumor differentiation), additional molecular genetic characteristics (BRAF, KRAS mutational status, mismatch repair genes (MMR)), and survival. RESULTS:HSP90 immunoreactivity was observed in various degrees. Fifty-one cases (14 %) were positive for Her2 (score 2+ and 3+) with 16/43 cases with Her2 2+ staining pattern showing amplification of Her2 determined by FISH. There was a significant correlation between high HSP90 expression and Her2 overexpression (p = 0.011). High HSP90 expression was associated with earlier tumor stages (p = 0.019), absence of lymph node (p = 0.006), and absence of distant metastases (p = 0.001). Patients with high tumoral HSP90 levels had a better survival (p = 0.032), but this was not independent from other prognostic relevant pathologic parameters. Her2 expression was not associated with any of the investigated histopathological, molecular, or clinical parameters. CONCLUSIONS: High HSP90 levels are reflecting lower malignant potential in colon cancer. Her2 positivity can be observed in a small number of cases. Targeting HSP90 and/or Her2 may be an alternative therapeutic approach in colon cancer in a subset of patients.
Authors: Marta Herreros-Villanueva; Maximiliano Rodrigo; Manuel Claver; Pilar Muñiz; Enrique Lastra; Carlos García-Girón; Maria Jesus Coma del Corral Journal: Mol Biol Rep Date: 2010-06-20 Impact factor: 2.316
Authors: Lena-Christin Conradi; Hanna Styczen; Thilo Sprenger; Hendrik A Wolff; Claus Rödel; Manuel Nietert; Kia Homayounfar; Jochen Gaedcke; Julia Kitz; Recca Talaulicar; Heinz Becker; Michael Ghadimi; Peter Middel; Tim Beissbarth; Josef Rüschoff; Torsten Liersch Journal: Am J Surg Pathol Date: 2013-04 Impact factor: 6.394
Authors: Sven A Lang; Dagmar Klein; Christian Moser; Andreas Gaumann; Gabriel Glockzin; Marc H Dahlke; Wolfgang Dietmaier; Ulrich Bolder; Hans J Schlitt; Edward K Geissler; Oliver Stoeltzing Journal: Mol Cancer Ther Date: 2007-03 Impact factor: 6.261
Authors: Mohammad Ilyas; Heike Grabsch; Ian O Ellis; Chris Womack; Robert Brown; Dan Berney; Dean Fennell; Manuel Salto-Tellez; Martin Jenkins; Goran Landberg; Richard Byers; Darren Treanor; David Harrison; Andrew R Green; Graham Ball; Peter Hamilton Journal: Histopathology Date: 2013-04-12 Impact factor: 5.087
Authors: Mark J Ranek; Marisa J Stachowski; Jonathan A Kirk; Monte S Willis Journal: Philos Trans R Soc Lond B Biol Sci Date: 2018-01-19 Impact factor: 6.237
Authors: Melina Helbling; Anne Lukesch; Aladin Haimovici; Eva Karamitopoulou; Martin D Berger; Marion Hädrich; Makhmud Mallaev; Beat Schnüriger; Viktor H Koelzer; Heather Dawson; Markus Borner; Rupert Langer; Robert Rosenberg; Ulrich Nitsche; Daniel Inderbitzin; Alessandro Lugli; Mario Tschan; Inti Zlobec Journal: Oncotarget Date: 2014-07-15
Authors: Diana Spiegelberg; Adrian Dascalu; Anja C Mortensen; Andris Abramenkovs; Gamze Kuku; Marika Nestor; Bo Stenerlöw Journal: Oncotarget Date: 2015-11-03
Authors: Jürgen Thanner; Christine Bekos; Cecilia Veraar; Stefan Janik; Maria Laggner; Panja M Boehm; Ana-Iris Schiefer; Leonhard Müllauer; Walter Klepetko; Hendrik Jan Ankersmit; Bernhard Moser Journal: Oncoimmunology Date: 2020-05-13 Impact factor: 8.110